BDTX: Black Diamond Therapeutics, Inc. Stock

by  •  • Comments Off on BDTX: Black Diamond Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 107.51
Enterprise Value ($M) 71.07
Book Value ($M) 83.28
Book Value / Share 1.47
Price / Book 1.29
NCAV ($M) 61.82
NCAV / Share 1.09
Price / NCAV 1.74

Profitability (mra)
Return on Invested Capital (ROIC) -0.66
Return on Assets (ROA) -0.44
Return on Equity (ROE) -0.60

Liquidity (mrq)
Quick Ratio 4.92
Current Ratio 4.92

Balance Sheet (mrq) ($M)
Current Assets 101.18
Assets 122.64
Liabilities 39.35
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -75.84
Net Income -69.68

Cash Flow Statement (mra) ($M)
Cash From Operations -62.30
Cash from Investing 16.97
Cash from Financing 25.55

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Bb Biotech Ag 15.10 0.00
11-14 13G Vestal Point Capital, LP 8.90
11-14 13G/A T. Rowe Price Investment Management, Inc. 19.00 0.70
11-08 13G BlackRock, Inc. 6.20 0.00
08-08 13D/A Versant Venture Capital VI, L.P. 7.70 0.00
05-13 13D/A New Enterprise Associates 16, L.P. 8.10 31.84
05-09 13D/A Ra Capital Management, L.p. 4.95 7.65

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ___________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193
2024-03-12 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ___________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 120,348 318,165 37.83
2025-03-06 48,826 175,280 27.86
2025-03-05 129,127 332,229 38.87
2025-03-04 216,666 654,547 33.10

(click for more detail)

Similar Companies
AVXL – Anavex Life Sciences Corp. BBIO – BridgeBio Pharma, Inc.
BCRX – BioCryst Pharmaceuticals, Inc. BEAM – Beam Therapeutics Inc.
BIIB – Biogen Inc.


Financial data and stock pages provided by
Fintel.io